Neil Vidwans, MD
Internal Medicine · Arlington, VANPI 1043201965
Payments from drug & device makers
Across 438 payments — averaging $21.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- AbbVie$1K
- Pfizer$1K
- Novo Nordisk$950
- Lilly USA, LLC$745
- Amgen$454
- plus $4K from 31 others
What the payments were for
- Food & beverage$9,20799%
- Education$561%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 54 | $1,276 |
| AbbVie(2 entities) | 63 | $1,206 |
| Pfizer | 73 | $1,082 |
| Novo Nordisk | 45 | $950 |
| Lilly USA, LLC | 30 | $745 |
| Amgen | 14 | $454 |
| Bayer | 9 | $333 |
| Merck | 18 | $314 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 18 | $311 |
| GSK | 12 | $308 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $269 |
| Viiv Healthcare Company | 9 | $221 |
| Boehringer Ingelheim | 11 | $209 |
| Johnson & Johnson | 6 | $209 |
| Gilead | 9 | $196 |
| Astellas Pharma US Inc | 8 | $187 |
| Exact Sciences | 6 | $158 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 6 | $154 |
| Supernus Pharmaceuticals, Inc. | 6 | $109 |
| Sanofi-aventis U.S. LLC | 5 | $79 |
| Avanir Pharmaceuticals, Inc. | 4 | $75 |
| Amarin Pharma, Inc. | 3 | $53 |
| Otsuka America Pharmaceutical, Inc. | 2 | $47 |
| Abbott | 2 | $43 |
| Inspire Medical Systems, Inc. | 1 | $33 |
| Baxter Healthcare | 1 | $26 |
| Cepheid | 1 | $26 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $24 |
| Novartis | 1 | $23 |
| Astellas Pharma Global Development | 1 | $22 |
| Kowa Pharmaceuticals America, Inc. | 1 | $21 |
| Teva Pharmaceuticals USA, Inc. | 1 | $21 |
| Corium, LLC | 1 | $19 |
| E.r. Squibb & Sons, L.L.C. | 1 | $17 |
| Esperion Therapeutics, Inc. | 1 | $17 |
| Sanofi Pasteur Inc. | 1 | $14 |
| Watermark Medical, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,263 in reported general payments places this provider in the 90th percentile of 2,724 internal medicine providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 24 | $52,390 |
| RelistorMethylnaltrexone Bromide | 16 | $46,346 |
| EliquisApixaban | 33 | $34,109 |
| MounjaroTirzepatide | 22 | $24,734 |
| FarxigaDapagliflozin Propanediol | 17 | $22,578 |
| LinzessLinaclotide | 30 | $20,488 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 17 | $14,739 |
| JanuviaSitagliptin Phosphate | 18 | $13,653 |
| Ambien CrZolpidem Tartrate | 12 | $7,341 |
| SynthroidLevothyroxine Sodium | 24 | $2,258 |
| Rosuvastatin Calcium | 88 | $2,153 |
| Oxycodone Hcl | 74 | $2,110 |
| Lidocaine | 16 | $1,814 |
| Fluticasone Propionate | 41 | $1,280 |
| Nebivolol Hcl | 25 | $1,211 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $950 | $52,39024 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor | $311 | $46,34616 claims |
| PfizerEliquis | $1,082 | $34,10933 claims |
| Lilly USA, LLCMounjaro | $745 | $24,73422 claims |
| AbbVieLinzess, Synthroid | $1,206 | $22,74654 claims |
| AstraZenecaFarxiga | $1,276 | $22,57817 claims |
| GSKTrelegy Ellipta | $308 | $14,73917 claims |
| MerckJanuvia | $314 | $13,65318 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,724 internal medicine providers in Virginia.
Other internal medicine in Arlington
- Denise BrunerArlington$227K
- Girja JallaArlington$139K
- Leroy VaughanRichmond$20.8M
- James ClarkCharlottesville$16.2M
- Nabil AndrawisBurke$8.5M
- Mary BlumbergNorfolk$6.5M
- David RamstadSuffolk$5.8M
- Andrew PoklepovicRichmond$4.6M
- Nashwa GabraBurke$4.3M
- Michael DevittCharlottesville$3.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.